Chronic Obstructive Pulmonary Disease Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1062596
  • May 2021
  • Pharmaceuticals
  • 134 Pages
The Chronic Obstructive Pulmonary Disease Drugs market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Chronic Obstructive Pulmonary Disease Drugs market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered AstraZeneca, Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Abbott, Astellas Pharma, Circassia Pharmaceuticals plc, Pfizer Inc., F. Hoffmann-La Roche Ltd
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Chronic Obstructive Pulmonary Disease Drugs market along with their effects over the forecast period. Similarly, according to the region Chronic Obstructive Pulmonary Disease Drugs market research report includes the study of opportunities available in the market situation.

The Chronic Obstructive Pulmonary Disease Drugs market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Chronic Obstructive Pulmonary Disease Drugs Market:
The Chronic Obstructive Pulmonary Disease Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. AstraZeneca, Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Abbott, Astellas Pharma, Circassia Pharmaceuticals plc, Pfizer Inc., F. Hoffmann-La Roche Ltd

Chronic Obstructive Pulmonary Disease Drugs Market Segmentation Analysis:
By Disease Type
Emphysema
Chronic Bronchitis
Therapy
Bronchodilators
Steroids
Anti-inflammatory Drugs
Others
End User
Hospitals
Clinics
Others

Global Chronic Obstructive Pulmonary Disease Drugs Market Segmentation by Regions:
In regional analysis, Chronic Obstructive Pulmonary Disease Drugs market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Chronic Obstructive Pulmonary Disease Drugs market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Chronic Obstructive Pulmonary Disease Drugs Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Chronic Obstructive Pulmonary Disease Drugs Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Chronic Obstructive Pulmonary Disease Drugs Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Chronic Obstructive Pulmonary Disease Drugs Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Chronic Obstructive Pulmonary Disease Drugs Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Chronic Obstructive Pulmonary Disease Drugs market, according to the key region.
  • To study the Chronic Obstructive Pulmonary Disease Drugs market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Chronic Obstructive Pulmonary Disease Drugs market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Chronic Obstructive Pulmonary Disease Drugs research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Chronic Obstructive Pulmonary Disease Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Chronic Obstructive Pulmonary Disease Drugs market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Chronic Obstructive Pulmonary Disease Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Chronic Obstructive Pulmonary Disease Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Chronic Obstructive Pulmonary Disease Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • GlaxoSmithKline plc
  • Abbott
  • Astellas Pharma
  • Circassia Pharmaceuticals plc
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Emphysema
  • Chronic Bronchitis
  • Hospitals
  • Clinics
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Chronic Obstructive Pulmonary Disease Drugs Market Snapshot
          2.1.1. Global Chronic Obstructive Pulmonary Disease Drugs Market By Disease Type,2019
               2.1.1.1.Emphysema
               2.1.1.2.Chronic Bronchitis
          2.1.2. Global Chronic Obstructive Pulmonary Disease Drugs Market By End User,2019
               2.1.2.1.Hospitals
               2.1.2.2.Clinics
               2.1.2.3.Others
          2.1.3. Global Chronic Obstructive Pulmonary Disease Drugs Market By End-use,2019
          2.1.4. Global Chronic Obstructive Pulmonary Disease Drugs Market By Geography,2019

3. Global Chronic Obstructive Pulmonary Disease Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Disease Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Disease Type, 2020
     4.2. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028

5. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028

6. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Chronic Obstructive Pulmonary Disease Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028
          7.2.3. North America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Chronic Obstructive Pulmonary Disease Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028
          7.3.3. Europe Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028
          7.4.3. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Chronic Obstructive Pulmonary Disease Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028
          7.5.3. Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Chronic Obstructive Pulmonary Disease Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By Disease Type, 2018 – 2028
          7.6.3. MEA Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Chronic Obstructive Pulmonary Disease Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Chronic Obstructive Pulmonary Disease Drugs Providers
        8.4.1 AstraZeneca
                8.4.1.1 Business Description
                8.4.1.2 AstraZeneca Geographic Operations
                8.4.1.3 AstraZeneca Financial Information
                8.4.1.4 AstraZeneca Product Positions/Portfolio
                8.4.1.5 AstraZeneca Key Developments
        8.4.2 Boehringer Ingelheim International GmbH
                8.4.2.1 Business Description
                8.4.2.2 Boehringer Ingelheim International GmbH Geographic Operations
                8.4.2.3 Boehringer Ingelheim International GmbH Financial Information
                8.4.2.4 Boehringer Ingelheim International GmbH Product Positions/Portfolio
                8.4.2.5 Boehringer Ingelheim International GmbH Key Developments
        8.4.3 Mylan N.V.
                8.4.3.1 Business Description
                8.4.3.2 Mylan N.V. Geographic Operations
                8.4.3.3 Mylan N.V. Financial Information
                8.4.3.4 Mylan N.V. Product Positions/Portfolio
                8.4.3.5 Mylan N.V. Key Developments
        8.4.4 Teva Pharmaceutical Industries Ltd
                8.4.4.1 Business Description
                8.4.4.2 Teva Pharmaceutical Industries Ltd Geographic Operations
                8.4.4.3 Teva Pharmaceutical Industries Ltd Financial Information
                8.4.4.4 Teva Pharmaceutical Industries Ltd Product Positions/Portfolio
                8.4.4.5 Teva Pharmaceutical Industries Ltd Key Developments
        8.4.5 GlaxoSmithKline plc
                8.4.5.1 Business Description
                8.4.5.2 GlaxoSmithKline plc Geographic Operations
                8.4.5.3 GlaxoSmithKline plc Financial Information
                8.4.5.4 GlaxoSmithKline plc Product Positions/Portfolio
                8.4.5.5 GlaxoSmithKline plc Key Developments
        8.4.6 Abbott
                8.4.6.1 Business Description
                8.4.6.2 Abbott Geographic Operations
                8.4.6.3 Abbott Financial Information
                8.4.6.4 Abbott Product Positions/Portfolio
                8.4.6.5 Abbott Key Developments
        8.4.7 Astellas Pharma
                8.4.7.1 Business Description
                8.4.7.2 Astellas Pharma Geographic Operations
                8.4.7.3 Astellas Pharma Financial Information
                8.4.7.4 Astellas Pharma Product Positions/Portfolio
                8.4.7.5 Astellas Pharma Key Developments
        8.4.8 Circassia Pharmaceuticals plc
                8.4.8.1 Business Description
                8.4.8.2 Circassia Pharmaceuticals plc Geographic Operations
                8.4.8.3 Circassia Pharmaceuticals plc Financial Information
                8.4.8.4 Circassia Pharmaceuticals plc Product Positions/Portfolio
                8.4.8.5 Circassia Pharmaceuticals plc Key Developments
        8.4.9 Pfizer Inc.
                8.4.9.1 Business Description
                8.4.9.2 Pfizer Inc. Geographic Operations
                8.4.9.3 Pfizer Inc. Financial Information
                8.4.9.4 Pfizer Inc. Product Positions/Portfolio
                8.4.9.5 Pfizer Inc. Key Developments
        8.4.10 F. Hoffmann-La Roche Ltd
                8.4.10.1 Business Description
                8.4.10.2 F. Hoffmann-La Roche Ltd Geographic Operations
                8.4.10.3 F. Hoffmann-La Roche Ltd Financial Information
                8.4.10.4 F. Hoffmann-La Roche Ltd Product Positions/Portfolio
                8.4.10.5 F. Hoffmann-La Roche Ltd Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Chronic Obstructive Pulmonary Disease Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By Disease Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By Disease Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By Disease Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By Disease Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By Disease Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Chronic Obstructive Pulmonary Disease Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Chronic Obstructive Pulmonary Disease Drugs: Market Segmentation 
FIG. 2 Global Chronic Obstructive Pulmonary Disease Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Chronic Obstructive Pulmonary Disease Drugs Market, By Disease Type, 2019 (US$ Mn) 
FIG. 5 Global Chronic Obstructive Pulmonary Disease Drugs Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Chronic Obstructive Pulmonary Disease Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Chronic Obstructive Pulmonary Disease Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Chronic Obstructive Pulmonary Disease Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Chronic Obstructive Pulmonary Disease Drugs Providers, 2019
FIG. 11 Global Chronic Obstructive Pulmonary Disease Drugs Market Revenue Contribution, By Disease Type, 2019 & 2028 (Value %) 
FIG. 12 Global Chronic Obstructive Pulmonary Disease Drugs Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Chronic Obstructive Pulmonary Disease Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Chronic Obstructive Pulmonary Disease Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Chronic Obstructive Pulmonary Disease Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Chronic Obstructive Pulmonary Disease Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Chronic Obstructive Pulmonary Disease Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Chronic Obstructive Pulmonary Disease Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Chronic Obstructive Pulmonary Disease Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Chronic Obstructive Pulmonary Disease Drugs Market Value, By Country, 2018 – 2028
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boehringer Ingelheim International GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mylan N.V.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Teva Pharmaceutical Industries Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbott: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Astellas Pharma: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Circassia Pharmaceuticals plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche Ltd: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Chronic Obstructive Pulmonary Disease Drugs Providers, 2016
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Chronic Bronchitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Chronic Obstructive Pulmonary Disease Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Chronic Obstructive Pulmonary Disease Drugs Market Value, 2018 – 2028, (US$ Mn)